Glutathione
FDA ApprovedAlso known as: GSH, L-Glutathione, Reduced Glutathione, Gamma-Glutamylcysteinylglycine
The master antioxidant and most abundant intracellular thiol in mammalian cells. This naturally occurring tripeptide (glutamate-cysteine-glycine) is essential for detoxification, immune function, and cellular protection. Extensively studied with strong mechanistic understanding and growing clinical evidence.
Research Statistics
Well-established antioxidant tripeptide; extensive global research with textbook-level mechanism.
Research Dossier
Overview
What is Glutathione and what does the research say?
Mechanism of Action
Glutathione is the most abundant intracellular antioxidant in mammalian cells, with well-characterized biochemistry supported by decades of research.
How It Works (Simplified)
Glutathione functions as a “master antioxidant” through several interconnected pathways:
Donates electrons to neutralize reactive oxygen species (ROS), preventing DNA, protein, and lipid damage before it occurs.
Conjugates to drugs and environmental toxins via glutathione S-transferases, making them water-soluble for excretion.
Regenerates vitamin C and vitamin E back to their active forms after they neutralize free radicals, amplifying antioxidant capacity.
Maintains T cell and NK cell function. Adequate intracellular GSH is required for lymphocyte proliferation and cytotoxic activity.
Scientific Pathways
GSH/GSSG Redox Cycle (Antioxidant Defense)
Reduced GSH (active) → Encounters ROS → Glutathione Peroxidase catalyzes
↓
GSH donates electrons → ROS neutralized
↓
Oxidized GSSG formed (2 GSH linked)
↓
Glutathione Reductase + NADPH
↓
GSSG recycled back to 2 GSHPhase II Detoxification (Xenobiotic Elimination)
Toxin/Drug → Phase I (CYP450) → Activated intermediate → GST conjugation → Water-soluble GSH conjugate → ExcretionKey Research: Richie JP et al. (2015) demonstrated that 6-month oral GSH supplementation increased body stores by 30-35%. PMID:24791752
Important Limitations
- Oral bioavailability historically debated; newer forms (liposomal, sublingual) show improved absorption
- GSH levels decline 10-15% per decade after age 20, accelerating in chronic disease
- Plasma half-life is short (~15-30 minutes); intracellular turnover varies by tissue
- Some clinical trials show inconsistent results depending on delivery method and population studied
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
Initial increases in plasma GSH levels may be observed. Liposomal forms show measurable increases in whole blood GSH within 1-2 weeks. Immune cell function improvements noted in some studies.
Continued accumulation of GSH in tissues. Clinical studies show significant increases in body stores by 4 weeks with consistent supplementation. Skin appearance improvements may begin.
Optimal benefits typically observed with sustained supplementation. Studies show 30-35% increases in body stores by 3-6 months. Liver function improvements noted in NAFLD studies at 4 months.
Long-term supplementation maintains elevated GSH levels. Benefits appear to be sustained with continued use. Discontinuation may result in gradual return to baseline levels.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate Glutathione product quality
Good Signs (6 indicators)
Warning Signs (5 indicators)
Bad Signs (6 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining Glutathione with other peptides. Based on published research and mechanistic considerations.
N-Acetylcysteine
SynergisticNAC is the primary precursor for GSH synthesis. Combining exogenous GSH with NAC may support both direct antioxidant activity and endogenous GSH production through complementary pathways.
Alpha-Lipoic-Acid
SynergisticAlpha-lipoic acid regenerates GSH and supports the GSH/GSSG redox cycle. Both compounds participate in antioxidant network recycling and may have complementary benefits.
Vitamin-C
SynergisticGSH regenerates oxidized vitamin C (dehydroascorbate) back to active ascorbate. This antioxidant recycling relationship suggests complementary benefits when combined.
BPC-157
CompatibleNon-overlapping mechanisms. GSH provides systemic antioxidant support while BPC-157 targets tissue repair pathways. No known contraindications.
Acetaminophen
CautionAcetaminophen depletes hepatic GSH stores during metabolism. High-dose acetaminophen use may increase GSH requirements; monitor liver function.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Glutathione
Glutathione Calculators
Related Peptides
Endoluten
Pineal cytamin, Pineal gland peptides, A-8 pineal peptides
A cytamin-class peptide supplement derived from pineal gland tissue, part of the Russian bioregulator framework. Marketed as an oral supplement for pineal function and melatonin support. Contains peptide complexes rather than defined sequences. No Western clinical validation.
Epithalon
Epitalon, Epithalone, AGAG +1 more
A synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Russian scientist Vladimir Khavinson, claimed to activate telomerase and extend lifespan. 2025 independent Western research confirmed telomerase activation in vitro. Still not approved anywhere; no controlled human clinical trials.
FOXO4-DRI
FOXO4-D-Retro-Inverso, FOXO4-DRI Peptide, Proxofim
A D-retro-inverso peptide designed to disrupt the FOXO4-p53 interaction, selectively eliminating senescent cells (senolytic). Preclinical studies in aged mice demonstrated restored fitness, fur density, and renal function. No human clinical trials conducted. More selective than BCL-2 inhibitors but remains unproven in humans.
Humanin
HN, HNG, S14G-Humanin +2 more
A 24-amino acid mitochondria-derived peptide (MDP) discovered in 2001 that shows cytoprotective, anti-apoptotic, and neuroprotective effects in preclinical studies. Represents a novel class of signaling molecules encoded within mitochondrial DNA. Extensive academic research with emerging interest in aging, metabolic disease, and neurodegeneration, but no approved clinical applications.
MOTS-c
Mitochondrial ORF of the 12S rRNA type-c, Mitochondrial-derived peptide, MOTS-C peptide
A 16-amino acid mitochondrial-derived peptide encoded in mtDNA that targets AMPK/mTOR pathways for metabolic regulation. Preclinical studies show exercise mimetic and geroprotective effects. Lower MOTS-c levels found in T2D patients. No clinical trials yet conducted in humans.
SHLP-2
Small Humanin-Like Peptide 2, SHLP2, Mitochondrial-Derived Peptide 2
A 26-amino acid mitochondria-derived peptide (MDP) discovered in 2016 from the same mitochondrial DNA region as humanin. Shows cytoprotective, metabolic, and potential longevity effects in preclinical studies. Part of an emerging class of mitochondrial signaling molecules, but human therapeutic data is lacking.